DLA Piper
Recent News About DLA Piper
-
DLA Piper advises Alimera Sciences in acquisition by ANI Pharmaceuticals
DLA Piper advised Alimera Sciences, Inc., a global pharmaceutical company focused on ophthalmic solutions, in its acquisition by ANI Pharmaceuticals, a diversified biopharmaceutical company, in a transaction that values Alimera at approximately US$381 million in up front consideration plus contingent value rights providing for additional consideration upon the achievement of certain revenue milestones.